Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae

Pharmacotherapy

Volumn 38, Issue 4, 2018, Pages 444-461

  Jorgensen, Sarah Christina Jane ^a   Rybak, Michael Joseph ^a,b,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DETROIT MEDICAL CENTER   (United States)

Author keywords

carbapenem resistant Enterobacteriaceae; Klebsiella pneumoniae carbapenemase; meropenem and vaborbactam; multidrug resistant

Indexed keywords

MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; VABORBACTAM; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; BORONIC ACID DERIVATIVE; CARBAPENEMASE; PORIN;

ABDOMINAL PAIN; ACUTE PYELONEPHRITIS; ALLERGIC REACTION; ANTIMICROBIAL ACTIVITY; APPLICATION SITE PAIN; AREA UNDER THE CURVE; ASPIRATION PNEUMONIA; BACTERICIDAL ACTIVITY; BIOCHEMISTRY; BLA GENE; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CHARLSON COMORBIDITY INDEX; CONTACT DERMATITIS; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESISTANCE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; GENE; GENE EXPRESSION; HEADACHE; HEART ARREST; HEMATOMA; HUMAN; HYPERTRANSAMINASEMIA; IN VITRO STUDY; INJECTION SITE PHLEBITIS; LETHARGY; MAXIMUM CONCENTRATION; MIC50; MIC90; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PHLEBITIS; REVIEW; SEIZURE; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; KLEBSIELLA INFECTION; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIAL PROTEINS; BETA-LACTAMASES; BORONIC ACIDS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; KLEBSIELLA INFECTIONS; MEROPENEM; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; PORINS; URINARY TRACT INFECTIONS;

EID: 85044476434     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.2092     Document Type: Review

References (80)

1. Doi Y, Bonomo RA, Hooper DC, et al. Gram-Negative bacterial infections: research priorities, accomplishments, and future directions of the antibacterial resistance leadership group. Clin Infect Dis 2017;64(Suppl_1):S30–5.
2. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007;3:440–58, table of contents.
3. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010;6:1119–25.
4. Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014;4:2322–8.
5. Balandin Moreno B, Fernandez Simon I, Pintado Garcia V, et al. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients. Scand J Infect Dis 2014;3:175–80.
6. Alexander EL, Loutit J, Tumbarello M, et al. Carbapenem-resistant Enterobacteriaceae infections: results from a retrospective series and implications for the design of prospective clinical trials. Open Forum Infect Dis 2017;2:ofx063.
7. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012;7:943–50.
8. Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 2017;61(8):pii: e00883-17.
9. van Duin D, Lok JJ, Earley M, et al. Colistin vs. ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 2018;66(2):163–71.
10. Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 2016;12:1615–8.
11. Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother 2017;61(2):pii: e01964-16.
12. King M, Heil E, Kuriakose S, et al. Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother 2017;61(7):pii: e00449-17.
13. Krapp F, Grant JL, Sutton SH, Ozer EA, Barr VO. Treating complicated carbapenem-resistant Enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation. Int J Antimicrob Agents 2017;6:770–3.
14. Hecker SJ, Reddy KR, Totrov M, et al. Discovery of a cyclic boronic acid beta-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem 2015;9:3682–92.
15. ® (meropenem-vaborbactam). Press release. Parsippany, NJ. April 11, 2016.
16. Product information: VABOMERE intravenous injection, meropenem-vaborbactam intravenous injection. Remplex Pharms/The Medicines Company (Per FDA). Parsippany, NJ. 2017.
17. Craig WA. The pharmacology of meropenem, a new carbapenem antibiotic. Clin Infect Dis 1997;24:S266–75.
18. Moellering RC Jr, Eliopoulos GM, Sentochnik DE. The carbapenems: new broad spectrum beta-lactam antibiotics. J Antimicrob Chemother 1989;24:1–7.
19. Martinez-Martinez L, Pascual A, Hernandez-Alles S, et al. Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob Agents Chemother 1999;7:1669–73.
20. Livermore DM. Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods. Eur J Clin Microbiol 1987;4:439–45.
21. King DT, Sobhanifar S, Strynadka NC. One ring to rule them all: current trends in combating bacterial resistance to the beta-lactams. Protein Sci 2016;4:787–803.
22. Ehmann DE, Jahic H, Ross PL, et al. Kinetics of avibactam inhibition against Class A, C, and D beta-lactamases. J Biol Chem 2013;39:27960–71.
23. Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother 2017;61(11):pii:e01443-17.
24. Griffith DC, Loutit JS, Morgan EE, Durso S, Dudley MN. Phase 1 study of the safety, tolerability, and pharmacokinetics of the beta-lactamase inhibitor vaborbactam (RPX7009) in healthy adult subjects. Antimicrob Agents Chemother 2016;10:6326–32.
25. Wenzler E, Gotfried MH, Loutit JS, et al. Meropenem-RPX7009 concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy adult subjects. Antimicrob Agents Chemother 2015;12:7232–9.
26. Trang M, Griffith DC, Bhavnani SM, et al. Population pharmacokinetics of meropenem and vaborbactam in healthy volunteers and infected patients. American Society for Microbiology Microbe. New Orleans, LA. June 1–5, 2017. Abstract 192.
27. Wei X, Jang SH, Florian J, Zhuang L. Clinical pharmacology and biopharmaceutics review. Meropenem-vaborbactam. NDA#209776. Remplex Pharmaceuticals. Division of Anti-Infective Products. Center or Drug Evaluation and Research. Silver Spring, MD: US Food and Drug Administration; 2017.
28. Drusano GL, Standiford HC, Bustamante C, et al. Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob Agents Chemother 1984;5:715–21.
29. Product information: MERREM intravenous injection, meropenem intravenous injection. AstraZeneca Pharmaceuticals LP (per FDA). Wilmington, NC. 2013.
30. Ambrose PG, Bhavnani SM, Ellis-Grosse EJ, Drusano GL. Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! Clin Infect Dis 2010;51:S103–10.
31. Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 2008;1:24–36.
32. Honeybourne D. Antibiotic penetration into lung tissues. Thorax 1994;2:104–6.
33. Lapuebla A, Abdallah M, Olafisoye O, et al. Activity of meropenem combined with RPX7009, a novel beta-lactamase inhibitor, against gram-negative clinical isolates in New York City. Antimicrob Agents Chemother 2015;8:4856–60.
34. Castanheira M, Rhomberg PR, Flamm RK, Jones RN. Effect of the beta-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2016;9:5454–8.
35. Castanheira M, Huband MD, Mendes RE, Flamm RK. Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother 2017;61(9):pii:e00567-17.
36. CLSI. Performance Standards for Antimicrobial Susceptibility Testing 27th Informational Supplement. CLSI document M100-S27. Clinical and Laboratory Standards Institute. Wayne, PA; 2017.
37. Grande Roche KK. Clinical microbiology review. Meropenem-vaborbactam. NDA#209776. Remplex Pharmaceuticals. Division of Anti-Infective Products. Center or Drug Evaluation and Research. US Food and Drug Administration; 2017.
38. Sabet M, Tarazi Z, Nolan T, et al. Activity of meropenem-vaborbactam in mouse models of infection due to KPC-producing carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother 2018;62(1):pii: e01446-17.
39. Sabet M, Tarazi Z, Rubio-Aparicio D, et al. Activity of simulated human dosage regimens of meropenem and vaborbactam against carbapenem-resistant Enterobacteriaceae in an in vitro hollow fiber model. Antimicrob Agents Chemother 2017;62(2):pii: e01969-17.
40. Humphries RM, Hindler JA. Emerging resistance, new antimicrobial agents. But no tests! The challenge of antimicrobial susceptibility testing in the current US regulatory landscape. Clin Infect Dis 2016;1:83–8.
41. Lomovskaya O, Griffith DC, Louitit JS, Dudley MN. Rationale for dose selection for Carbavance (CVC; meropenem/RPX7009) in Phase 3 trials. IDWeek 2014. Philadelphia, PA. October 8–12, 2014. Abstract 794.
42. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003;10:1116–23.
43. Lodise TP, Sorgel F, Melnick D, Mason B, Kinzig M, Drusano GL. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2011;4:1606–10.
44. Sabet M, Tarazi Z, Nolan T, et al. Activity of meropenem-vaborbactam in mouse models of infection due to KPC-producing carbapenem-resistant Enterobacteriaceae (CRE). Antimicrob Agents Chemother 2017;62(2):pii: e01969-17.
45. Frippiat F, Musuamba FT, Seidel L, et al. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study. J Antimicrob Chemother 2015;1:207–16.
46. Oshima K, Nakamura S, Iwanaga N, et al. Efficacy of high-dose meropenem (six grams per day) in treatment of experimental murine pneumonia induced by meropenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2017;61(1):pii: e02056-16.
47. Bhagunde P, Chang KT, Hirsch EB, Ledesma KR, Nikolaou M, Tam VH. Novel modeling framework to guide design of optimal dosing strategies for beta-lactamase inhibitors. Antimicrob Agents Chemother 2012;5:2237–40.
48. Livermore DM. Determinants of the activity of beta-lactamase inhibitor combinations. J Antimicrob Chemother 1993;31:9–21.
49. Sun D, Rubio-Aparicio D, Nelson K, Dudley MN, Lomovskaya O. Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2017;61(12):pii: e01694-17.
50. Grobner S, Linke D, Schutz W, et al. Emergence of carbapenem-non-susceptible extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates at the university hospital of Tubingen, Germany. J Med Microbiol 2009;58(Pt 7):912–22.
51. Findlay J, Hamouda A, Dancer SJ, Amyes SG. Rapid acquisition of decreased carbapenem susceptibility in a strain of Klebsiella pneumoniae arising during meropenem therapy. Clin Microbiol Infect 2012;2:140–6.
52. Lagace-Wiens P, Walkty A, Karlowsky JA. Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid 2014;9:13–25.
53. Product information: AVYCAZ intravenous injection, ceftazidime-avibactam intravenous injection. Cerexa (Per FDA). Madison, NJ; 2017.
54. Masi M, Pages JM. Structure, function and regulation of outer membrane proteins involved in drug transport in Enterobactericeae: the OmpF/C–TolC Case. Open Microbiol J 2013;7:22–33.
55. Lomovskaya O, Castanheira M, Vazquez J, et al. Assessment of MIC increases with meropenem-vaborbactam (VABOMERE) and ceftazidime-avibactam in TANGO II (a Phase 3 study of the treatment of CRE infections). Presented at IDWeek 2017, October 4-8, 2017, San Diego, CA. Abstract 1874
56. Livermore DM, Warner M, Jamrozy D, et al. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother 2015;9:5324–30.
57. Haidar G, Clancy CJ, Shields RK, Hao B, Cheng S, Nguyen MH. Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2017;61(5):pii: e02534-16.
58. Shields RK, Chen L, Cheng S, et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 2017;61(3):pii: e02097-16.
59. Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. In vitro selection of meropenem resistance among ceftazidime-avibactam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases. Antimicrob Agents Chemother 2017;61(5):e00079-17.
60. Nelson K, Hemarajata P, Sun D, et al. Resistance to ceftazidime-avibactam is due to transposition of KPC in a porin-deficient strain of Klebsiella pneumoniae with increased efflux activity. Antimicrob Agents Chemother 2017;61:e00989-17.
61. Shen Z, Ding B, Ye M, et al. High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother 2017;72(7):1930–6.
62. Castanheira M, Mendes RE, Sader HS. Low frequency of ceftazidime-avibactam resistance among Enterobacteriaceae isolates carrying blaKPC collected in U.S. hospitals from 2012 to 2015. Antimicrob Agents Chemother 2017;61(3):pii: e02369-16.
63. Rubin D, Higgins K. Statistical review. Meropenem-vaborbactam. NDA#209776. Remplex Pharmaceuticals. Division of Anti-Infective Products. Center or Drug Evaluation and Research. US Food and Drug Administration; 2017.
64. Kapoor R. Clinical review. Meropenem-vaborbactam. NDA#209776. Remplex Pharmaceuticals. Division of Anti-Infective Products. Center or Drug Evaluation and Research. US Food and Drug Administration; 2017.
65. Kaye KS, File T, Shorr A, et al. Clinical outcomes with meropenem-vaborbactam (M-V) by extended-spectrum beta-lactamase (ESBL) production in TANGO 1, a Phase 3 randomized trial vs piperacillin-tazobactam (P-T). American Society for Microbiology Microbe. New Orleans, LA. June 1–5, 2017. Abstract 305
66. Castanheira M, Huband MD, Mendes RE, Flamm RK. Meropenem-vaborbactam tested against contemporary gram-negative. Antimicrob Agents Chemother 2017;61(9):pii: e00567-17.
67. Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis 2016;6:754–62.
68. Sims M, Mariyanovski V, McLeroth P, et al. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother 2017;72(9):2616–26.
69. Identifier NCTClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 02168946. Efficacy, safety, tolerability of carbavance compared to best available therapy in serious infections due to carbapenem resistant Enterobacteriaceae, in adults. Posted June 20, 2014; updated August 8, 2017. Available from https://clinicaltrials.gov/ct2/show/NCT02168946?term=vaborbactam&rank=4. Accessed November 20, 2017.
70. Boucher HW. Challenges in anti-infective development in the era of bad bugs, no drugs: a regulatory perspective using the example of bloodstream infection as an indication. Clin Infect Dis 2010;50:S4–9.
71. Nambiar S, Laessig K, Toerner J, Farley J, Cox E. Antibacterial drug development: challenges, recent developments, and future considerations. Clin Pharmacol Ther 2014;2:147–9.
72. Kaye KS, Vazquez J, Daikos G, et al. Clinical Outcomes of Serious Infections due to Carbapenem-Resistant Enterobacteriaceae (CRE) in TANGO II, a Phase 3, Randomized, Multi-National, Open-Label Trial of Meropenem-Vaborbactam (M-V) Versus Best Available Therapy (BAT). IDWeek 2017. San Diego, CA. October 4–8, 2017. Abstract 1862.
73. Paterson DL, Kwak EJ, Bhowmick T, et al. Meropenem-Vaborbactam vs. Best Available Therapy for Carbapenem-Resistant Enterobacteriaceae Infections in TANGO II: Outcomes in Immunocompromised Patients. IDWeek 2017. San Diego, CA. October 4-8, 2017. Abstract 1868.
74. Wunderink R, Giamarellos-Bourboulis E, Rahav G, et al. Meropenem-vaborbactam vs. best available therapy for carbapenem-resistant Enterobacteriaceae infections in TANGO II: primary outcomes by site of infection. Presented at IDWeek 2017, October 4-8, 2017, San Diego, CA. Abstract 1867
75. The Medicines Company. The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam (formerly, Carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE. Press release. July 25, 2017.
76. Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV. In vitro activity of biapenem plus RPX7009, a carbapenem combined with a serine beta-lactamase inhibitor, against anaerobic bacteria. Antimicrob Agents Chemother 2013;6:2620–30.
77. Patel JB, Giles RE. Meropenem: evidence of lack of proconvulsive tendency in mice. J Antimicrob Chemother 1989;24:307–9.
78. De Sarro A, Ammendola D, Zappala M, Grasso S, De Sarro GB. Relationship between structure and convulsant properties of some beta-lactam antibiotics following intracerebroventricular microinjection in rats. Antimicrob Agents Chemother 1995;1:232–7.
79. Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995;1:73–101.
80. Haidar G, Clancy CJ, Chen L, et al. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother 2017;61(9):pii: e00642-17.